Re: Zenith Epigenetics is proud to announce the appointment Dr. Brad Thompson, PhD to our Board of Directors!
posted on
Feb 08, 2022 07:09PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
"I could be dreaming but the potentional in a few years is there"
no arguement here or on anything else you pointed out.
I'd just like to ride that wave on the Naz + look at the price were doing PP's for now compared to your valuations, its brutal.
With the right people leading the way to a Naz listing this thing would soar + make the next 2-3 years a bit more enjoyable/interesting IMO.